Port Angeles

Researchers are evaluating the safety and effects of a medicine called Mevrometostat for treating adults with Relapsed/Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC), and Follicular Lymphoma (FL). This Phase 1 study includes three parts; Parts 1 and 2 have finished enrolling, while Part 3 is currently open and focuses on men with CRPC who have progressed after prior treatment. The study aims to understand the safety profile, toxicities, and preliminary effectiveness of Mevrometostat alone or combined with other treatments. Participants in Part 3 receive oral Mevrometostat and/or enzalutamide. Part 3 has two substudies: a Bioequivalence (BE) substudy where participants take three single doses of Mevrometostat in separate periods, and a Drug-Drug Interaction (DDI) substudy with two cohorts. Cohort 1 receives Mevrometostat twice daily and/or itraconazole once daily, while Cohort 2 receives Mevrometostat twice daily, enzalutamide once daily, and/or itraconazole once daily. After the assessment phase, all participants enter a maintenance phase taking Mevrometostat twice daily and enzalutamide once daily until their cancer no longer responds. Throughout the study, participants will have regular evaluations including monitoring for dose limiting toxicities, adverse events, laboratory abnormalities, vital signs, and disease response. The study will track radiographic progression-free survival until disease progression or death, up to approximately two years. This close monitoring aims to gather data on the safety, tolerability, and effects of the treatments over time.

Researchers are investigating how real-time audio-video telemedicine consultations with a neonatologist, called teleneonatology, affect early health outcomes of at-risk newborns delivered in community hospitals. This multicenter study uses a stepped wedge cluster randomized design to assess the impact of teleneonatology on early mortality, morbidity, and delivery room care in these newborns. The study involves connecting a neonatologist in a regional neonatal intensive care unit (NICU) with physicians in community hospitals through a live, two-way audio-video telemedicine system. This connection allows neonatologists to provide advanced support during neonatal resuscitations remotely. The study focuses on neonates born at less than 32 weeks gestation or those needing advanced resuscitation such as prolonged positive pressure ventilation, alternative airway placement, or chest compressions. Participants will include both community hospital clinicians attending newborn resuscitations and the at-risk neonates meeting the inclusion criteria. Researchers will measure outcomes such as the 7-day mortality rate to evaluate the effect of teleneonatology. The study excludes neonates with severe congenital anomalies requiring early intensive care or surgery, those receiving comfort care only, and cases where an in-person neonatologist or transport team is present at birth.